ArticleJTO clinical and research reports2026

Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results.

Tatsuya Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.